143 related articles for article (PubMed ID: 20473132)
1. The arsenic exposure hypothesis for Alzheimer disease.
Gong G; OʼBryant SE
Alzheimer Dis Assoc Disord; 2010; 24(4):311-6. PubMed ID: 20473132
[TBL] [Abstract][Full Text] [Related]
2. Chronic noise exposure and Alzheimer disease: Is there an etiological association?
Cui B; Li K
Med Hypotheses; 2013 Oct; 81(4):623-6. PubMed ID: 23899629
[TBL] [Abstract][Full Text] [Related]
3. Arsenic exposure and cardiovascular disorders: an overview.
Balakumar P; Kaur J
Cardiovasc Toxicol; 2009 Dec; 9(4):169-76. PubMed ID: 19787300
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
5. An aluminum-based rat model for Alzheimer's disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration.
Walton JR
J Inorg Biochem; 2007 Sep; 101(9):1275-84. PubMed ID: 17662457
[TBL] [Abstract][Full Text] [Related]
6. Amyloid-beta, tau, and dementia.
Takashima A
J Alzheimers Dis; 2009; 17(4):729-36. PubMed ID: 19542626
[TBL] [Abstract][Full Text] [Related]
7. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease.
Reddy PH
J Neurochem; 2006 Jan; 96(1):1-13. PubMed ID: 16305625
[TBL] [Abstract][Full Text] [Related]
8. [Fusion of field and laboratory studies on the investigation of arsenic].
Kumagai Y
Yakugaku Zasshi; 2009 Oct; 129(10):1177-85. PubMed ID: 19797872
[TBL] [Abstract][Full Text] [Related]
9. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
Bloom GS
JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
[TBL] [Abstract][Full Text] [Related]
10. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan.
Tseng CH; Huang YK; Huang YL; Chung CJ; Yang MH; Chen CJ; Hsueh YM
Toxicol Appl Pharmacol; 2005 Aug; 206(3):299-308. PubMed ID: 16039941
[TBL] [Abstract][Full Text] [Related]
11. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
12. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
Roy S; Rauk A
Med Hypotheses; 2005; 65(1):123-37. PubMed ID: 15893129
[TBL] [Abstract][Full Text] [Related]
13. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function.
Bennett DA; Schneider JA; Wilson RS; Bienias JL; Arnold SE
Arch Neurol; 2004 Mar; 61(3):378-84. PubMed ID: 15023815
[TBL] [Abstract][Full Text] [Related]
14. Early molecular changes in Alzheimer disease: can we catch the disease in its presymptomatic phase?
Wirz KT; Keitel S; Swaab DF; Verhaagen J; Bossers K
J Alzheimers Dis; 2014; 38(4):719-40. PubMed ID: 24072070
[TBL] [Abstract][Full Text] [Related]
15. A new insight on Al-maltolate-treated aged rabbit as Alzheimer's animal model.
Bharathi ; Shamasundar NM; Sathyanarayana Rao TS; Dhanunjaya Naidu M; Ravid R; Rao KS
Brain Res Rev; 2006 Sep; 52(2):275-92. PubMed ID: 16782202
[TBL] [Abstract][Full Text] [Related]
16. Toxicity mechanisms of arsenic that are shared with neurodegenerative diseases and cognitive impairment: Role of oxidative stress and inflammatory responses.
Escudero-Lourdes C
Neurotoxicology; 2016 Mar; 53():223-235. PubMed ID: 26868456
[TBL] [Abstract][Full Text] [Related]
17. [Treatment strategy of Alzheimer's disease: pause in clinical trials of Abeta vaccine and next steps].
Kuzuhara S
Brain Nerve; 2010 Jul; 62(7):659-66. PubMed ID: 20675870
[TBL] [Abstract][Full Text] [Related]
18. Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies.
Iqbal K; Grundke-Iqbal I
Acta Neuropathol; 2005 Jan; 109(1):25-31. PubMed ID: 15645264
[TBL] [Abstract][Full Text] [Related]
19. Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease.
Resende R; Moreira PI; Proença T; Deshpande A; Busciglio J; Pereira C; Oliveira CR
Free Radic Biol Med; 2008 Jun; 44(12):2051-7. PubMed ID: 18423383
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
